PGG might have modulating effects on RAS downstream signaling via MEK/ERK/PI3K/AKT/mTOR, all being promising drug targets for treating KRAS mutant NSCLC (Tomasini et al., 2016). The gene discussed is MTOR; the disease is non-small cell lung carcinoma.